These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 29477574)

  • 1. Cost-effectiveness of hepatitis C screening and treatment linkage intervention in US methadone maintenance treatment programs.
    Schackman BR; Gutkind S; Morgan JR; Leff JA; Behrends CN; Delucchi KL; McKnight C; Perlman DC; Masson CL; Linas BP
    Drug Alcohol Depend; 2018 Apr; 185():411-420. PubMed ID: 29477574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of Hepatitis C Virus Treatment Models for People Who Inject Drugs in Opioid Agonist Treatment Programs.
    Gutkind S; Schackman BR; Morgan JR; Leff JA; Agyemang L; Murphy SM; Akiyama MJ; Norton BL; Litwin AH; Linas BP
    Clin Infect Dis; 2020 Mar; 70(7):1397-1405. PubMed ID: 31095683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of scaling-up HCV prevention and treatment in the United States for people who inject drugs.
    Barbosa C; Fraser H; Hoerger TJ; Leib A; Havens JR; Young A; Kral A; Page K; Evans J; Zibbell J; Hariri S; Vellozzi C; Nerlander L; Ward JW; Vickerman P
    Addiction; 2019 Dec; 114(12):2267-2278. PubMed ID: 31307116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
    Hartwell D; Jones J; Baxter L; Shepherd J
    Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs.
    Schackman BR; Leff JA; Barter DM; DiLorenzo MA; Feaster DJ; Metsch LR; Freedberg KA; Linas BP
    Addiction; 2015 Jan; 110(1):129-43. PubMed ID: 25291977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies.
    Krauth C; Rossol S; Ortsäter G; Kautz A; Krüger K; Herder B; Stahmeyer JT
    BMC Infect Dis; 2019 Dec; 19(1):1019. PubMed ID: 31791253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings.
    Rein DB; Smith BD; Wittenborn JS; Lesesne SB; Wagner LD; Roblin DW; Patel N; Ward JW; Weinbaum CM
    Ann Intern Med; 2012 Feb; 156(4):263-70. PubMed ID: 22056542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In an era of highly effective treatment, hepatitis C screening of the United States general population should be considered.
    Younossi Z; Blissett D; Blissett R; Henry L; Younossi Y; Beckerman R; Hunt S
    Liver Int; 2018 Feb; 38(2):258-265. PubMed ID: 28719013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost Effectiveness of Universal Screening for Hepatitis C Virus Infection in the Era of Direct-Acting, Pangenotypic Treatment Regimens.
    Eckman MH; Ward JW; Sherman KE
    Clin Gastroenterol Hepatol; 2019 Apr; 17(5):930-939.e9. PubMed ID: 30201597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population.
    Chahal HS; Marseille EA; Tice JA; Pearson SD; Ollendorf DA; Fox RK; Kahn JG
    JAMA Intern Med; 2016 Jan; 176(1):65-73. PubMed ID: 26595724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients.
    Linas BP; Barter DM; Leff JA; DiLorenzo M; Schackman BR; Horsburgh CR; Assoumou SA; Salomon JA; Weinstein MC; Kim AY; Freedberg KA
    AIDS; 2014 Jan; 28(3):365-76. PubMed ID: 24670522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of opioid substitution therapies in the treatment of opioid use disorder: results of a UK cost-effectiveness modelling study.
    Kenworthy J; Yi Y; Wright A; Brown J; Maria Madrigal A; Dunlop WCN
    J Med Econ; 2017 Jul; 20(7):740-748. PubMed ID: 28489467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study.
    Ferrante SA; Chhatwal J; Brass CA; El Khoury AC; Poordad F; Bronowicki JP; Elbasha EH
    BMC Infect Dis; 2013 Apr; 13():190. PubMed ID: 23621902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of full and partial opioid agonists for opioid use disorder in outpatient settings: United States healthcare sector perspective.
    Choi SA; Yan CH; Gastala NM; Touchette DR; Stranges PM
    J Subst Use Addict Treat; 2024 May; 160():209237. PubMed ID: 38061629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness Analysis of Early Treatment of Chronic HCV with Sofosbuvir/Velpatasvir in Italy.
    Ruggeri M; Romano F; Basile M; Coretti S; Rolli FR; Drago C; Cicchetti A
    Appl Health Econ Health Policy; 2018 Oct; 16(5):711-722. PubMed ID: 30039348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness and health-related outcomes of screening for hepatitis C in Korean population.
    Kim KA; Chung W; Choi HY; Ki M; Jang ES; Jeong SH
    Liver Int; 2019 Jan; 39(1):60-69. PubMed ID: 29998565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of Universal and Targeted Hepatitis C Virus Screening in the United States.
    Tatar M; Keeshin SW; Mailliard M; Wilson FA
    JAMA Netw Open; 2020 Sep; 3(9):e2015756. PubMed ID: 32880650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: a modeling analysis for Ukraine.
    Alistar SS; Owens DK; Brandeau ML
    PLoS Med; 2011 Mar; 8(3):e1000423. PubMed ID: 21390264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Microsimulation Study of the Cost-Effectiveness of Hepatitis C Virus Screening Frequencies in Hemodialysis Centers.
    Epstein RL; Pramanick T; Baptiste D; Buzzee B; Reese PP; Linas BP; Sawinski D
    J Am Soc Nephrol; 2023 Feb; 34(2):205-219. PubMed ID: 36735375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of methadone maintenance treatment for HIV-positive drug users in Vietnam.
    Tran BX; Ohinmaa A; Duong AT; Do NT; Nguyen LT; Mills S; Houston S; Jacobs P
    AIDS Care; 2012; 24(3):283-90. PubMed ID: 21936718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.